ASTH — Astrana Health, Inc.

Summary of Astrana Health, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $950.5 million, up 43% year-over-year.
• Full Year 2025 Revenue: $3.2 billion, representing 56% year-over-year growth.
• Adjusted EBITDA: Q4 at $52.5 million (up 50% YoY); full year at $205.4 million (up 21% YoY).
• Free Cash Flow: $104.5 million for the full year, with a conversion rate of over 50% relative to adjusted EBITDA.
• Net Income: $6 million for Q4, with adjusted EPS of $0.54; full year adjusted EPS at $2.20.
• Cash Position: $429.5 million in cash and $648.7 million in net debt, with a net leverage ratio of 2.6 times.

2. Strategic Updates and Business Highlights

• Membership Growth: Ended 2025 with 1.6 million members in value-based care arrangements, with a mid-single-digit growth in Medicare Advantage membership.
• Geographic Diversification: Revenue from California grew 50% YoY, while revenue from other markets grew 90% YoY, indicating a balanced revenue base.
• Integration of Prospect Health: The integration is on track, with strong provider retention (over 97% gross retention) and expected annualized synergies of $12 million to $15 million.
• Technology and AI Utilization: Continued investment in AI tools to enhance operational efficiency, automate workflows, and improve clinical outcomes.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $3.8 billion and $4.1 billion; adjusted EBITDA between $250 million and $280 million.
• Q1 2026 Guidance: Revenue expected between $900 million and $1.0 billion; adjusted EBITDA between $60 million and $70 million.
• Cost Trends: Anticipated medical cost trend for 2026 is slightly over 5%, with expectations of continued control over costs.

4. Bad News, Challenges, or Points of Concern

• Material Weakness in Internal Controls: A Form 12b-25 will be filed due to a material weakness related to acquisition accounting processes, although no material misstatements were reported.
• Medicaid and Exchange Disenrollment: Expected disenrollment rates of approximately 10% for Medicaid and low double digits for exchange members, which could negatively impact revenue.
• Competitive Pressures: The company faces challenges from elevated medical cost trends across the industry, although it believes its model can manage these pressures effectively.

5. Notable Q&A Insights

• Cost Trend Expectations: Management expects a conservative cost trend of just over 5% for 2026, with variations across different patient segments.
• Guidance Range Clarification: The wider EBITDA guidance range reflects both headwinds (e.g., Medicaid disenrollment) and tailwinds (e.g., improved Medicare Advantage rates).
• AI Tools and Future Opportunities: The company is leveraging AI to enhance operational efficiency and reduce costs, with significant investments in AI infrastructure expected to yield further improvements.
• Prospect Integration Metrics: Early metrics show strong engagement and wellness visit rates, with expectations for continued improvement as integration progresses.

Overall, Astrana Health, Inc. demonstrated strong financial performance in 2025, with a clear strategic focus on disciplined growth and integration. However, challenges related to regulatory changes and market dynamics remain a concern as the company moves into 2026.